High Circulating FGF-23 and Its Relationship with Severity of Spinal Involvement in Diffuse Idiopathic Skeletal Hyperostosis

Zhou, Haicheng; Xu, Hongpan; Gong, Jianmin; Li, Zhiyang; Sun, Xu

doi:10.1007/s00223-023-01134-8

Calcif Tissue Int

2023

DOI: 10.1007/s00223-023-01134-8

|View full text |Cite

High Circulating FGF-23 and Its Relationship with Severity of Spinal Involvement in Diffuse Idiopathic Skeletal Hyperostosis

Haicheng Zhou,

Hongpan Xu,

Jianmin Gong

et al.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2024

Publication Types

Select...

Preprint1

Relationship

Self Cite0

Independent1

Authors

Journals

Cited by 1 publication

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

The prevalence of ENPP1 deficiency and the preclinical efficacy of ENPP1 biologic therapy in OPLL.

Braddock,

Srivast,

Kato

et al. 2024

Preprint

View full text Add to dashboard Cite

Ossification of the Posterior Longitudinal Ligament (OPLL) and Diffuse Idiopathic Skeletal Hyperostosis (DISH) are disorders in which patients suffer from pain and stiffness due to progressive spinal fractures and enthesospathy. Myelopathy and impaired mobility worsen with age and may progress to hemiplegia; the mechanisms driving disease progression are unknown, and effective treatments are lacking. To investigate OPLL disease pathogenesis we prospectively quantiated plasma PPi in consecutive OPLL and cervical osteoarthritic (OA) patients who presented for surgical correction, and further sequenced the OPLL patients for genes associated with phosphate wasting and spinal enthesopathy, and to evaluate novel OPLL therapeutics we explored the efficacy of soluble and bone targeted ENPP1 biologics on the plasma biomarkers and the skeletal phenotype of OPLL mice. We found that a significant proportion of OPLL patients harbored monoallelic pathogenic ENPP1 loss of function variants and that those OPLL patients requiring surgical intervention had significantly reduced plasma PPi levels in comparison to cervical OA patients with comparably severe disease. In murine OPLL, bone targeted ENPP1-Fc corrected plasma biomarkers and spinal hyperostosis, significantly improved or normalized spinal and long bone fragility, and ameliorated Achilles tendon enthesopathy. Our findings support the notion that OPLL patients are ENPP1 deficient, and that treatment with ENPP1 biologics may ameliorate the spinal hyperostosis, fracture risk, and enthesopathies present in OPLL.

show abstract

The prevalence of ENPP1 deficiency and the preclinical efficacy of ENPP1 biologic therapy in OPLL.

Braddock,

Srivast,

Kato

et al. 2024

Preprint

View full text Add to dashboard Cite

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

High Circulating FGF-23 and Its Relationship with Severity of Spinal Involvement in Diffuse Idiopathic Skeletal Hyperostosis

Cited by 1 publication

References 26 publications

The prevalence of ENPP1 deficiency and the preclinical efficacy of ENPP1 biologic therapy in OPLL.

The prevalence of ENPP1 deficiency and the preclinical efficacy of ENPP1 biologic therapy in OPLL.

Contact Info

Product

Resources

About